Prolaris: Your NEW ADT decision tool When it comes to treating NCCN intermediate- and high-risk prostate cancer, it can be challenging to know which patients could truly benefit from the use of ADT (Androgen Deprivation Therapy)  + RT (Radiation Therapy). The Prolaris white paper tells our exclusive story of consistent data across our validation and utility studies; giving you confidence to choose Prolaris when you need to know which patients would have little to no benefit from ADT. Request Prolaris White Paper If for some reason you don’t receive the email with your white paper downlo ..read more

Treating prostate cancer can be hard, Prolaris makes it easy Knowing if your prostate cancer patients are safe for active surveillance or if they would benefit from active treatment can be challenging. The Prolaris white paper tells our exclusive story of consistent data across our validation and utility studies; giving you confidence to choose Prolaris when making treatment decisions between AS and active treatment. Request Prolaris White Paper If for some reason you don’t receive the email with your white paper download, make sure to check your junk folder. Physician First Name Physician ..read more

Against the backdrop of recent shifts in the genetic testing industry, we would like to take a minute to reiterate Myriad Genetics’ determination to bring clinically useful and easy-to-use genetic and genomic testing products to your practice and patients.   For 31 years, Myriad Genetics has been a leader in genetic testing and precision medicine. For the past 10+ years, we have been providing genetic insights in urology. To date, more than three million patients have benefited from being tested with our products: Prolaris®, MyRisk™, and BRACAnalysis CDx®. This robust experience creates a ..read more

Connect with us The AUA National meeting is centered around the exploration of the latest and groundbreaking advancements in urology, and there is no better time than now to discover how incorporating genetic testing into your practice may provide you with clinically actionable information to optimize and personalize prostate cancer treatment. Improve patient outcomes Not all prostate cancer behaves the same, and traditional diagnostic tools do not measure how quickly the cancer is growing. Prolaris is a prognostic, tumor-based biomarker test that looks at cell cycle proliferation genes (CCP ..read more

Historically, Urologists in practice have given Radiation Therapy (RT) or Androgen Deprivation Therapy (ADT) after initial prostate cancer treatment to reduce the risk of their patient’s cancer returning. However, a New Study from Radiation Oncologist, Jonathan Tward M.D., Ph.D., has demonstrated there is no benefit for select men. Watch the video below to learn more about this study and how the new Prolaris® multi-modal threshold can personalize patient treatment. Want to Learn More? Prolaris Makes Treatment Decisions Easier Every man with prostate cancer, regardless of his NCCN risk gro ..read more

Myriad Genetics announces new data validating the prognostic power of the Prolaris multi-modal threshold and its ability to help predict which men with aggressive prostate cancer will benefit from advanced hormonal therapy and which patients with lower-risk prostate cancer can safely avoid such treatments. In 2018, the United States Preventive Services Task Force identified up to 50% of prostate cancers were over diagnosed which may result in overtreatment1. By accurately predicting the aggressiveness of the tumor, the Prolaris test can help reduce the number of over diagnosed cases and guide ..read more

Knowing the status of your patient’s BRCA 1/2 germline status is critical. Myriad hereditary cancer tests give you definitive and actionable risk stratification insights that directly impact current and future treatment decisions. Integrating germline testing early in your patients’ diagnostic workup is now easier than ever. Patients with localized prostate cancer and a BRCA mutation are: 6x more likely to die from prostate cancer within 5 years 4x more likely to develop metastasis within 5 years Live ~7 years less on average If you would like to learn more about BRACAnalysis CDx® or myRisk ..read more

Myriad Genetics, a leader in molecular diagnostics and precision medicine, announced that Medicare has expanded coverage for BRACAnalysis CDx® for men with prostate cancer who are eligible or could become eligible for treatment with Lynparza® (olaparib). BRACAnalysis CDx is the only germline test covered for this indication. To view full press release click here: PRESS RELEASE If you would like to learn more about BRACAnalysis CDx® or myRisk®, click here. The post Medicare Expands Coverage for BRACAnalysis CDx in Prostate Cancer appeared first on Prolaris ..read more

A ..read more

A ..read more